Swayampakula Ramakanth, an analyst from H.C. Wainwright, maintained the Buy rating on Actuate Therapeutics, Inc.. The associated price target remains the same with $20.00.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Swayampakula Ramakanth has given his Buy rating due to a combination of factors surrounding Actuate Therapeutics, Inc.’s strategic regulatory plans and promising clinical data. The company’s management is actively pursuing Breakthrough Therapy Designation for elraglusib, which could accelerate its approval process through the Real-Time Oncology Review program. This strategic move is bolstered by positive data from a Phase 2 study, showing significant improvement in survival rates for patients treated with elraglusib in combination with other therapies.
Furthermore, the financial projections and valuation analysis support a positive outlook. Despite reporting no revenues for 2Q25, the company’s cash reserves are deemed sufficient to sustain operations into late 2025. The analyst’s valuation, based on a risk-adjusted net present value analysis, suggests a 12-month price target of $20 per share. However, potential risks such as financial, clinical, and regulatory challenges are acknowledged, yet the overall assessment leans towards a favorable long-term potential for ACTU.